#United States #New York #Shareholder Rights #Pacira BioSciences #PCRX

Important Notice for Pacira BioSciences Shareholders

Levi & Korsinsky, LLP, a recognized leader in securities litigation, has released a notification for investors in Pacira BioSciences, Inc. (NASDAQ: PCRX). This communication concerns a class action lawsuit that seeks to address alleged securities fraud affecting shareholders during the period from August 2, 2023, to August 8, 2024.

Overview of the Class Action Lawsuit

The class action aims to recover losses suffered by investors who believe they were misled about the company’s financial health and known risks. The lawsuit highlights a significant event that occurred on August 9, 2024, when Pacira issued a press release revealing the result of a lawsuit it was involved in regarding patent infringement against eVenus. The court invalidated Pacira’s U.S. Patent No. 11,033,495, which is crucial for the company’s flagship product, Exparel.

The invalidity of this patent is alarming since Exparel represents approximately 80% of Pacira's revenue. Industry analysts have indicated that this news raises substantial concerns about the strength of Pacira’s remaining patents, potentially allowing for more generic competition and leading to increased legal expenses.

This revelation triggered a major decline in the company's stock price, which plummeted by over 47% on the following day, dropping from $22.36 to $11.70 per share. Such drastic changes in market value illustrate the impact that legal and financial risks can have on investor wealth and market perception.

Action Steps for Affected Investors

The deadline to apply for lead plaintiff status in this class action is March 14, 2025. Even if you choose not to pursue this status, you may still be eligible for any recoveries resulting from the lawsuit. Potential participants in this suit should be aware that joining the class comes at no upfront cost—class members may receive compensation without any out-of-pocket expenses.

Levi & Korsinsky has committed itself to represent shareholders over the last two decades, successfully recovering hundreds of millions of dollars on behalf of investors. With a strong track record in securities litigation, they have ranked among the top firms according to ISS Securities Class Action Services.

Why Choose Levi & Korsinsky?

With a dedicated team of over 70 professionals, Levi & Korsinsky's expertise in complex securities litigation makes them a trusted ally for shareholders seeking justice. They are passionate about fighting for their clients' rights, ensuring that investors are well-informed of their options. Shareholders interested in learning more about their rights or joining the lawsuit against Pacira can reach out directly via email or through their dedicated phone number.

For further inquiries, please contact:

• - Joseph E. Levi, Esq.
• - Ed Korsinsky, Esq.
• - Office: 33 Whitehall Street, 17th Floor, New York, NY 10004
• - Phone: (212) 363-7500
• - Email: email protected]
• - Website: [www.zlk.com

Stay informed and protect your investments.

Conclusion

As such situations unfold, remaining vigilant and informed is vital. The upcoming March 14, 2025 deadline is critical for all affected shareholders of Pacira BioSciences. Make sure to consult with legal experts and take appropriate action in the interests of your financial well-being.